Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Patient-controlled midazolam anxiolysis should not yet change practice; leaves open its feasibility, efficacy, and safety for prospective trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Loper et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: